Please login to the form below

Not currently logged in
Email:
Password:

New associate director at Packer Forbes

Samantha Bremner joins from Wave Healthcare Communications
Samantha Bremner

Healthcare communications firm Packer Forbes Communications has appointed Samantha Bremner as associate director.

Packer Forbers said the appointment was a response to new business growth for the agency.

Bremner has experience on both the agency and client side of medical communications, including most recently as programme director at Wave Healthcare Communications.

Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked with Packer Forbes. She also had a spell at Merck Serono.

Joella Webber, managing director, Packer Forbes said: “We have known Sam since she was our client at Actelion and we are delighted to welcome her back to our team in a different guise. We know Sam will bring inspiration and fantastic expertise to us as an agency and to her new clients; we are already enjoying working with her.”

30th January 2015

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....